MARKET WIRECNBC • 1h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ALGS Stock dropped -2.71% Today — RQD Quant Desk Flash
$5.03 -2.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Aligos Therapeutics Inc. (ALGS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $31.4M
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALGS)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALGS Stock dropped -2.71% Today — RQD Quant Desk Flash
Aligos Therapeutics Inc. (ALGS) dropped -2.71% to $5.03, trading at 11% of its 52-week range ($3.98 – $13.69). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($3.98 – $13.69) with RSI-14 at 41.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.03 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ALGS Headlines & Catalysts
MARKET WIRECNBC • 2h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 3h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 5h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 6h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 6h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 6h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALGS)
- ✓Walkthrough of ALGS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALGS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.03%▲ ASCENDING CHANNEL
2026-10-30O $4.99H $5.05L $4.75C $5.03VOL 23.8K
RES: $8.70SUP: $4.59SMA50: $5.56SMA200: $6.24
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALGS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -39.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALGS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALGS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALGS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALGS)
Health Care Rank #988 of 1016
⚔️ MGX vs ALGS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALGS vs. MGX, ESLA, GNTA, EVAX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aligos Therapeutics Inc. (ALGS) ranks #988 by composite RQD confidence (26/100, grade E) and #800 by equity capitalization ($31.4M). Within this direct 5-issuer industry benchmark cohort, ALGS leads on earnings valuation at N/A trailing P/E, while ALGS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ALGS at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALGS
ACTIVE
Aligos Therapeutics Inc. | E | 26/100 | — | — | -35.0% | -2.71% | $31.4M | Benchmark Subject |
| MGX Metagenomi Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | +1.03% | $31.4M | /mgx-vs-algs → |
| ESLA Estrella Immunopharma Inc. | D- | 41/100 | — | — | -35.0% | -11.32% | $31.7M | /esla-vs-algs → |
| GNTA Genenta Science S.p.A. | C | 62/100 | — | — | — | +2.48% | $29.9M | /gnta-vs-algs → |
| EVAX Evaxion A/S | D+ | 58/100 | — | — | — | -0.96% | $27.8M | /evax-vs-algs → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799448In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aligos Therapeutics Inc. (ALGS) reported GAAP revenue of $2.2M (-39.5% vs. FY2024 revenue of $3.6M , and -64.7% cumulative change since FY2023) , GAAP net income of -$24.2M, operating cash flow of -$82.5M, and free cash flow of -$82.5M (-2.0% YoY). On the balance sheet, ALGS closed FY2025 with $88.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.2M | -$24.2M | -$82.5M | -$82.5M | $88.5M | — |
| FY2024 (FY) | 2024-12-31 | $3.6M | -$131.2M | -$80.7M | -$80.9M | $70.1M | — |
| FY2023 (FY) | 2023-12-31 | $6.2M | -$87.7M | -$79.0M | -$79.0M | — | — |
3. ALGS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALGS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aligos Therapeutics Inc. (NASDAQ: ALGS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $5.03 (-2.71% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALGS ranks #988 in composite RQD confidence.
How does ALGS compare to MGX and ESLA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALGS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ALGS leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALGS?
Per ALGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799448), Aligos Therapeutics Inc. generated $2.2M in revenue (-39.5% YoY), -$24.2M in net income, and -$82.5M in free cash flow against $88.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALGS trading relative to its 50-day, 200-day, and 52-week technical levels?
ALGS last traded at $5.03 (-2.71% on volume of 47,209 shares), positioning the stock -9.53% below its 50-day simple moving average ($5.56) and -19.39% below its 200-day simple moving average ($6.24). Across its 52-week range of $3.98 to $13.69, ALGS sits at the 10.8% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.40 to $5.66).
ALGS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALGS stock moving today?
Why ALGS Stock dropped -2.71% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.